Kala Hopes To Stride Into Dry Eye Market This Year

 
• By Jo Shorthouse

Kala Pharmaceuticals is hoping to shake up the dry eye market with a NDA filing this year for its steroid eye drop KPI-121 0.25%.

Vision
KPI-121 0.25% uses mucus-penetrating particle technology

More from Sensory

More from Therapy Areas